Zhang H - Search Results

1

Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.

Gao W, Hu H, Dai L, He M, Yuan H, Zhang H, Liao J, Wen B, Li Y, Palmisano M, Traore MDM, Zhou S, Sun D. Gao W, et al. Among authors: zhang h. Acta Pharm Sin B. 2022 May;12(5):2462-2478. doi: 10.1016/j.apsb.2022.02.015. Epub 2022 Feb 23. Acta Pharm Sin B. 2022. PMID: 35646532 Free PMC article.

2

Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.

Luo R, Li Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, Sun D. Luo R, et al. Among authors: zhang h. Int J Pharm. 2017 Mar 15;519(1-2):1-10. doi: 10.1016/j.ijpharm.2017.01.002. Epub 2017 Jan 4. Int J Pharm. 2017. PMID: 28063903

3

Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.

Li F, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai MP, Yuan H, Sun D. Li F, et al. Among authors: zhang h. Mol Pharm. 2018 Oct 1;15(10):4505-4516. doi: 10.1021/acs.molpharmaceut.8b00527. Epub 2018 Sep 21. Mol Pharm. 2018. PMID: 30180593 Free PMC article.

4

Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans.

Li YF, Zhang C, Zhou S, He M, Zhang H, Chen N, Li F, Luan X, Pai M, Yuan H, Sun D, Li Y. Li YF, et al. Among authors: zhang c, zhang h. Clin Pharmacol. 2018 Nov 8;10:165-174. doi: 10.2147/CPAA.S185449. eCollection 2018. Clin Pharmacol. 2018. PMID: 30519122 Free PMC article.

5

Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel.

Li F, Yuan H, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai M, Sun D. Li F, et al. Among authors: zhang h. Mol Pharm. 2019 Jun 3;16(6):2385-2393. doi: 10.1021/acs.molpharmaceut.8b01314. Epub 2019 May 1. Mol Pharm. 2019. PMID: 31002261 Free PMC article.

6

Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.

Luan X, Yuan H, Song Y, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S, Gao W, Sun D. Luan X, et al. Among authors: zhang h. Biomaterials. 2021 Aug;275:120910. doi: 10.1016/j.biomaterials.2021.120910. Epub 2021 Jun 3. Biomaterials. 2021. PMID: 34144373 Free PMC article.

7

Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.

Bailey CM, Liu Y, Peng G, Zhang H, He M, Sun D, Zheng P, Liu Y, Wang Y. Bailey CM, et al. Among authors: zhang h. Nanomedicine. 2020 Oct;29:102278. doi: 10.1016/j.nano.2020.102278. Epub 2020 Jul 30. Nanomedicine. 2020. PMID: 32738299 Free PMC article.

8

In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.

Koenigsknecht MJ, Baker JR, Wen B, Frances A, Zhang H, Yu A, Zhao T, Tsume Y, Pai MP, Bleske BE, Zhang X, Lionberger R, Lee A, Amidon GL, Hasler WL, Sun D. Koenigsknecht MJ, et al. Among authors: zhang h, zhang x. Mol Pharm. 2017 Dec 4;14(12):4295-4304. doi: 10.1021/acs.molpharmaceut.7b00425. Epub 2017 Oct 5. Mol Pharm. 2017. PMID: 28937221 Free PMC article. Clinical Trial.

9

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.

Wang Y, Liu Y, Bailey C, Zhang H, He M, Sun D, Zhang P, Parkin B, Baer MR, Zheng P, Malek SN, Liu Y. Wang Y, et al. Among authors: zhang p, zhang h. Oncogene. 2020 Apr;39(14):3015-3027. doi: 10.1038/s41388-020-1201-z. Epub 2020 Feb 15. Oncogene. 2020. PMID: 32060420 Free PMC article.

10

Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial.

Ji H, Zhao X, Chen X, Fang H, Gao H, Wei G, Zhang M, Kuang H, Yang B, Cai X, Su Y, Piao C, Zhao S, Li L, Sun W, Xu T, Xu Q, Fan Y, Ye J, Yao C, Shang M, Song G, Chen L, Zheng Q, Xiao X, Yan L, Lian F, Tong X, Jia Z; FOCUS Trial Committees and Investigators. Ji H, et al. JAMA Intern Med. 2024 Jun 3. doi: 10.1001/jamainternmed.2024.1190. Online ahead of print. JAMA Intern Med. 2024. PMID: 38829648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

120,302 results

Search Page